Hormonal
Daily subcutaneous administration of the dual GLP-1/glucagon receptor agonist MEDI0382 produces superior weight loss and fat mass reduction in diet-induced obese mice and cynomolgus monkeys compared to the GLP-1 analogue liraglutide, driven by glucagon receptor-mediated increases in energy expenditure.
For individuals seeking significant weight loss and metabolic improvement, dual GLP-1/glucagon receptor agonists like MEDI0382 offer superior fat loss compared to GLP-1-only treatments. This is achieved through daily subcutaneous injections that leverage both satiety signals (GLP-1) and increased energy expenditure (glucagon). While effective in animal models, human clinical application requires medical supervision due to the hormonal nature of the intervention.
MEDI0382 produced superior weight loss and comparable glucose lowering to the GLP-1 peptide analogue liraglutide when administered daily at comparable doses in DIO mice. The additional fat mass reduction elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor.
Why this rating
High-quality preclinical data in both rodents and non-human primates, though not human clinical trials.
Source
Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates
Susan Henderson et al. · Diabetes Obesity and Metabolism · 2016
DOI 10.1111/dom.12735
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →